Dysregulation of JAK3 signalling, either through gain-of-function mutations or constitutive activation, has been implicated in a variety of immune disorders and malignancies, including acute lymphoblastic leukemia, T-cell prolymphocytic leukemia, cutaneous T-cell lymphoma, and certain solid tumors [4–6]. Here, JAK3 is linked to immune system disorder.